|
시장보고서
상품코드
2112456
리드리스 심박조율기 : 시장 인사이트, 경쟁 구도 및 시장 예측(-2034년)Leadless Pacemakers - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요:
- 리드리스 심박조율기 시장은 2025년 4억 2,770만 달러로 추산되며, 2034년까지 10억 10만 달러에 달할 것으로 전망됩니다. 이러한 성장의 배경에는 전 세계적으로 서맥성 부정맥의 부담이 증가하고, 저침습적 리드리스 심장 리듬 관리로 임상적 전환이 이루어지고 있으며, 이중 챔버 및 심장 재동기화 치료(CRT)(CRT)의 적응증이 상업적으로 확대되고 있기 때문입니다.
- 전 세계 리드리스 심박조율기 시장은 2026년부터 2034년까지의 예측 기간 동안 연평균 성장률(CAGR) 9.6%로 성장하고 있습니다.
- 제품 유형별로는 2025년에 단일 챔버형 리드리스 심박조율기 부문이 68%의 점유율을 차지하며 리드리스 심박조율기 시장을 주도했습니다.
- 기술별로는 2025년에 능동 고정 기술 부문이 58%의 점유율을 차지하며 리드리스 심박조율기 시장을 주도했습니다.
- 적응증별로는 2025년에 서맥 부문이 52.3%의 점유율을 차지하며 리드리스 심박조율기 시장을 주도했습니다.
- 최종 사용자별로는 2025년에 병원 부문이 55.9%의 점유율을 차지하며 리드리스 심장박동기 시장을 주도했습니다.
- 북미는 2025년에 42%의 점유율을 차지하며 전 세계 리드리스 심박조율기 시장의 매출을 견인했고, 지역별로는 전 세계에서 가장 높은 시장 점유율을 기록했습니다.
리드리스 심박조율기는 저침습 카테터를 이용한 경정맥적 접근법을 통해 심강 내에 직접 이식되는 소형 자립형 심장 리듬 관리 기기로, 기존 심박조율기에 필요했던 경정맥 리드나 피하 펄스 발생기 포켓이 필요하지 않습니다. 기존 심박조율기의 약 10분의 1 크기인 이 장치들은 배터리, 전자 회로 및 페이싱 전극을 단일 캡슐 내에 통합하고 심내막에 고정되므로, 리드나 포켓으로 인한 골절, 탈락, 감염, 정맥 폐색 등의 합병증 위험을 줄여줍니다. 시장은 제품 유형별(단실형 및 이중실형 시스템), 기술별(수동 고정, 능동 고정, 기기 간 무선 통신, 기타 신흥 접근법 포함), 적응증별(서맥, 방실(AV) 차단, 심방세동이 중심), 최종 사용자별(병원, 심장 전문 의료 센터, 외래수술센터(ASC))로 분류됩니다. 듀얼 챔버 이식형 기기 간(i2i) 통신 기술의 상용화,CRT(심장 재동기화 치료(CRT))용 리드리스 좌심실 내막 페이싱의 등장, 그리고 심박수 저하성 부정맥 발생률이 높아지는 고령화 사회를 배경으로, 리드리스 심박조율기는 전 세계 심장 리듬 관리 분야에서 점점 더 주류적인 선택지로 자리 잡고 있습니다.
리드리스 심박조율기 시장의 주요 성장 요인
- 듀얼 챔버형 리드리스 페이싱의 상업적 확장이 수요를 견인하고 있으며, 2023년 7월 FDA 승인을 받은 애보트(Abbott)의 ‘Aveir DR’ 시스템을 통해 심장의 두 심실에 대한 페이싱이 필요한 페이서 환자의 약 80%에게 리드리스 치료가 가능해졌습니다.
- 심혈관 질환 및 서맥성 부정맥의 전 세계적 부담이 증가함에 따라 페이싱 요법에 대한 수요가 확대되고 있습니다. 세계보건기구(WHO)에 따르면, 연간 약 1,790만 명의 사망이 심혈관 질환에 기인하는 것으로 추정됩니다.
- 병원과 전기생리학 센터에서는 리드나 포켓과 관련된 감염, 탈락, 재시술의 위험을 줄이고, 회복 기간을 단축하며, 시술 부담을 경감하기 위해 경정맥형 심박조율기 대신 리드리스 시스템의 도입이 점점 더 확대되고 있습니다.
- 메드트로닉(Medtronic)의 ‘Micra AV2’ 및 ‘VR2’(2023년 5월 FDA 승인, 2024년 1월 CE 마크 획득) 등, 더 긴 배터리 수명과 자동 AV 동기화 알고리즘을 갖춘 차세대 제품의 승인 및 적응증 확대로 인해 임상 현장에서의 도입이 확산되고 있습니다.
- 2025년 4월 FDA가 승인한 EBR Systems사의 ‘WiSE CRT 시스템’은 심장 재동기화 치료(CRT)(CRT)용 최초의 리드리스 좌심실 내막 심박조율기로, 이번 승인을 통해 리드리스 기술이 심부전 및 CRT 분야로 확대되고 있습니다.
- Aveir VR, AR, DR에 대한 CMS의 ‘증거 개발을 수반한 보험 적용(Coverage with Evidence Development)’ 연구와 WiSE CRT를 지지하는 메디케어의 보험 적용 결정 등, 유리한 보험 환급 동향에 힘입어 최대 시장에서의 도입 장벽이 완화되고 있습니다.
- 의사 대상 교육 확대, 전기생리학적 인프라 확충, 그리고 인도 등 신흥 시장에서의 이식 건수 증가(인도에서는 Abbott와 Max Hospital, Saket이 2025년 10월 인도 최초의 듀얼 챔버형 Aveir 이식을 시행했습니다)로 인해 지리적 확장 범위가 확대되고 있습니다.
- 듀얼 챔버 제품의 상용화, CRT의 확대, 고령화, 그리고 유리한 보험 환급 환경이 맞물려 2034년까지 시장은 10%대 후반에서 20%대 초반의 높은 성장률을 유지할 것으로 예측됩니다.
리드리스 심박조율기 시장 성장에 기여하는 요인
시장 성장 촉진요인
듀얼 챔버형 리드리스 심장박동기의 상업적 확대
리드리스 심박조율기 시장의 가장 강력한 촉진요인은 듀얼 챔버형 리드리스 심박조율기의 상업적 부상입니다. 2023년 7월 FDA 승인을 받은 애보트(Abbott)사의 ‘Aveir DR’ 시스템은 세계 최초의 듀얼 챔버형 리드리스 심박조율기 시스템으로, 이전에 승인된 심실용 기기 ‘Aveir VR’과 새로 승인된 심방용 기기 ‘Aveir AR’을기기 간 통신(i2i) 기술을 통해 연동시키고 있습니다. 심박조율기가 필요한 환자의 약 80%는 심장의 두 심실에 대한 치료가 필요하기 때문에 듀얼 챔버 승인으로 인해 기존 리드리스 시스템이 대상으로 삼았던 단일 심실성 서맥 환자를 넘어 대상 환자층이 대폭 확대될 것입니다. 애보트사는 Aveir 제품군의 도입 가속화가 2025년까지 심장 리듬 관리 사업에서 두 자릿수의 매출 성장을 가져왔습니다고 보고하고 있으며, 2025년 10월 인도 최초의 듀얼 챔버형 Aveir 이식 장치 출시를 포함하여,추가적인 임상적·지리적 확장을 통해 예측 기간 동안 수요가 지속될 것으로 전망됩니다.
세계 심혈관 질환 및 서맥성 부정맥의 부담 증가
세계적으로 증가하고 있는 심혈관 질환의 부담으로 인해, 심박조율기 치료 및 이를 제공하는 의료기기에 대한 수요가 확대되고 있습니다. 세계보건기구(WHO)에 따르면, 연간 약 1,790만 명의 사망이 심혈관 질환에 기인하며, 북미, 유럽,아시아태평양의 고령화에 따라 영구형 심박조율기 치료가 필요한 서맥, 방실 차단 및 기타 전도 장애의 발생률이 증가하고 있습니다. 리드리스 심박조율기는 기존 시스템에 수반되는 리드나 포켓 관련 합병증을 배제할 수 있어, 이러한 환자들에게 1순위 선택지로 점점 더 주목받고 있습니다. 고령화에 따라 부정맥 및 전도 장애의 유병률이 높아짐에 따라, 이식 수술 건수 및 이를 뒷받침하는 CDMO형 제조·임상 인프라는 2034년까지 꾸준히 확대될 것으로 예측됩니다.
시장 성장 억제요인
강한 성장세를 보이고 있음에도 불구하고, 리드리스 심박조율기 시장은 중대한 제약에 직면해 있습니다. 기존의 경정맥형 심박조율기에 비해 리드리스 기기의 초기 비용이 높은 점은 특히 가격에 민감하고 보험 급여율이 낮은 의료 제도에서 여전히 큰 장벽으로 작용하고 있으며, 충분한 자원을 보유한 병원이나 전문 의료 센터 이외의 곳에서의 도입을 제한할 가능성이 있습니다. 시술의 복잡성과 전문적인 전기생리학 교육이 필요하다는 점 때문에 이식 수술을 수행할 수 있는 의사의 수는 제한적입니다. 또한, 2021년 FDA가 발표한 안전성 정보에서는 초기 세대의 리드리스 심박조율기와 관련된 심벽 천공의 잠재적 위험이 지적되어, 일부 임상 현장에서는 여전히 신중한 도입 태도를 보이고 있습니다. 기기 제거 및 장기간에 걸친 복수 기기의 관리, 특히 환자가 평생에 걸쳐 여러 개의 리드리스 이식 기기를 축적하는 경우, 혈관 및 심내막에 대한 만성적인 부담과 관련된 미해결 과제가 발생하고 있습니다. 새로운 듀얼 챔버 및 CRT 적응증용 리드리스 시스템에 대한 보험 지급 정책은 미국 및 소수의 선진국 시장을 제외하고는 여전히 불균일하며, 시장은 승인된 소수의 제조업체에 집중된 상태입니다. 이로 인해 가격 경쟁이 제한되고, 비용 제약이 있는 의료 시스템에서의 도입이 둔화될 가능성이 있습니다. 이러한 비용, 교육, 안전성 모니터링 및 보험 환급과 관련된 장벽들이 복합적으로 작용함에 따라, 최소 침습 치료의 보급을 뒷받침하는 근본적인 요인인 고령화와 적응증 확대가 여전히 확고하게 존재함에도 불구하고 성장 속도는 둔화되고 있습니다.
자주 묻는 질문
목차
제1장 리드리스 심박조율기 시장 : 서론
제2장 리드리스 심박조율기 시장 : 주요 요약
제3장 리드리스 심박조율기 시장 : 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제 동향
제5장 규제 분석
제6장 Porter의 Five Forces 분석
제7장 리드리스 심박조율기 시장 : 평가
제8장 리드리스 심박조율기 시장 : 경쟁 구도
제9장 리드리스 심박조율기 시장 : 스타트업의 자금조달 및 투자 동향
제10장 리드리스 심박조율기 시장 : 기업 개요 및 제품 개요
제10장 수컷 콜
제11장 KOL(Key Opinion Leader)의 견해
제12장 프로젝트 접근
제13장 DelveInsight에 대해
제14장 면책사항 및 문의
LSH 26.08.21Leadless Pacemakers Market Summary
Overview:
- The Leadless Pacemakers market is estimated at USD 427.7 million in 2025 and is projected to reach USD 1,000.1 million by 2034. Growth is anchored in the rising global burden of bradyarrhythmia, the clinical shift toward minimally invasive, lead-free cardiac rhythm management, and the commercial expansion of dual-chamber and cardiac resynchronization therapy (CRT) indications.
- The global Leadless Pacemakers market is growing at a CAGR of 9.6% during the forecast period from 2026 to 2034.
- By product type, the single-chamber leadless pacemakers segment dominated the Leadless Pacemakers market with a 68% share in 2025.
- By technology, the active fixation technology segment dominated the Leadless Pacemakers market with a 58% share in 2025.
- By indication, the bradycardia segment dominated the Leadless Pacemakers market with a 52.3% share in 2025.
- By end-user, the hospitals segment dominated the Leadless Pacemakers market with a 55.9% share in 2025.
- North America dominated the global Leadless Pacemakers market revenue with a 42% share in 2025, representing the highest regional market share globally.
A leadless pacemaker is a miniaturized, self-contained cardiac rhythm management device that is implanted directly inside a heart chamber via a minimally invasive, catheter-based transvenous approach, eliminating the transvenous leads and subcutaneous pulse-generator pocket required by conventional pacemakers. Roughly one-tenth the size of a traditional pacemaker, these devices combine the battery, electronics, and pacing electrode within a single capsule that is fixed to the endocardium, reducing exposure to lead-related and pocket-related complications such as fracture, dislodgement, infection, and venous obstruction. The market is organized by product type across single-chamber and dual-chamber systems; by technology, including passive fixation, active fixation, wireless device-to-device communication, and other emerging approaches; by indication, led by bradycardia, atrioventricular (AV) block, and atrial fibrillation; and by end-user, spanning hospitals, cardiac specialty centers, and ambulatory surgical centers. Driven by the commercial rollout of dual-chamber implant-to-implant (i2i) communication technology, the entry of leadless left ventricular endocardial pacing for CRT, and an aging population with rising bradyarrhythmia incidence, leadless pacemakers have become an increasingly mainstream alternative within the global cardiac rhythm management landscape.
Leadless Pacemakers Market Key Growth Drivers
- The commercial expansion of dual-chamber leadless pacing is driving demand, with Abbott's Aveir DR system, approved by the FDA in July 2023, unlocking leadless therapy for the roughly 80% of pacemaker patients who require pacing in two heart chambers.
- The rising global burden of cardiovascular disease and bradyarrhythmia is expanding demand for pacing therapy, with the World Health Organization attributing nearly 17.9 million deaths annually to cardiovascular disease.
- Hospitals and electrophysiology centers are increasingly adopting leadless systems over transvenous pacemakers to reduce lead- and pocket-related infection, dislodgement, and reintervention risk, shortening recovery time and procedural burden.
- Next-generation product approvals and label expansions, including Medtronic's Micra AV2 and VR2 (FDA approval May 2023; CE Mark January 2024) offering longer battery life and automated AV-synchrony algorithms, are broadening clinical adoption.
- The April 2025 FDA approval of EBR Systems' WiSE CRT System, the first leadless left ventricular endocardial pacing device for cardiac resynchronization therapy, is extending leadless technology into the heart-failure and CRT segment.
- Favorable reimbursement momentum, including CMS Coverage with Evidence Development studies for Aveir VR, AR, and DR and a Medicare coverage decision supporting WiSE CRT, is easing adoption barriers in the largest market.
- Growing physician training, expanding electrophysiology infrastructure, and rising implant volumes in emerging markets such as India, where Abbott and Max Hospital, Saket launched the country's first dual-chamber Aveir implant in October 2025, are widening geographic reach.
- The convergence of dual-chamber commercialization, CRT expansion, an aging population, and favorable reimbursement is expected to sustain high-single-digit to low-double-digit growth in the market through 2034.
Key Companies in Leadless Pacemakers Market
The competitive landscape is led by the following active manufacturers:
- Abbott
- Medtronic
- BIOTRONIK
- Boston Scientific
- MicroPort Scientific Corporation
- Lepu Medical
- OSYPKA
- Shree Pacetronix
- EBR Systems
- Oscor
Factors Contributing to the Growth of the Leadless Pacemakers Market
Market Drivers
Commercial Expansion of Dual-Chamber Leadless Pacing
The most powerful driver of the Leadless Pacemakers market is the commercial rise of dual-chamber leadless pacing. Abbott's Aveir DR system, approved by the FDA in July 2023, was the world's first dual-chamber leadless pacing system, pairing the previously approved Aveir VR ventricular device with the newly authorized Aveir AR atrial device through implant-to-implant (i2i) communication technology. Because roughly 80% of patients who require pacing need therapy in two chambers of the heart, dual-chamber approval materially widens the addressable population beyond the single-chamber bradycardia patients historically served by leadless systems. Abbott reported that accelerating adoption of its Aveir portfolio drove double-digit sales growth in its Cardiac Rhythm Management business through 2025, and further clinical and geographic rollout, including the October 2025 launch of India's first dual-chamber Aveir implant, is expected to sustain demand through the forecast period.
Rising Global Cardiovascular Disease and Bradyarrhythmia Burden
The growing global burden of cardiovascular disease is expanding demand for pacing therapy and the devices that deliver it. The World Health Organization attributes nearly 17.9 million deaths annually to cardiovascular disease, and aging populations across North America, Europe, and Asia-Pacific are experiencing rising incidence of bradycardia, atrioventricular block, and other conduction disorders that require permanent pacing. Leadless pacemakers are increasingly considered a first-line option for these patients because they eliminate the lead- and pocket-related complications associated with conventional systems. As the prevalence of arrhythmia and conduction disease rises alongside an aging population, the volume of implant procedures and the CDMO-like manufacturing and clinical infrastructure that supports them is expected to grow steadily through 2034.
Market Restraints
Despite strong momentum, the Leadless Pacemakers market faces material constraints. The high upfront cost of leadless devices relative to conventional transvenous pacemakers remains a significant barrier, particularly in price-sensitive and lower-reimbursement healthcare systems, and can limit adoption outside well-resourced hospitals and specialty centers. Procedural complexity and the need for specialized electrophysiology training constrain the pool of physicians able to perform implants, and the 2021 FDA safety communication highlighting a potential risk of cardiac perforation associated with early leadless pacemaker generations continues to inform cautious adoption in some clinical settings. Device retrieval and long-term multi-device management, particularly as patients accumulate more than one leadless implant over a lifetime, raise unresolved questions around chronic vessel and endocardial burden. Reimbursement policy for newer dual-chamber and CRT-indicated leadless systems remains uneven outside the United States and a small number of developed markets, and the market remains concentrated among a limited number of approved manufacturers, which can constrain price competition and slow adoption in cost-constrained health systems. Together, these cost, training, safety-surveillance, and reimbursement barriers temper the pace of growth even as the underlying drivers of minimally invasive adoption, an aging population, and expanding indications remain firmly intact.
Leadless Pacemakers Market Segment Analysis
The leadless pacemakers market by product type (single-chamber leadless pacemakers and dual-chamber leadless pacemakers), technology (passive fixation technology, active fixation technology, wireless device-to-device communication, and others), indication (bradycardia, atrioventricular (av) block, atrial fibrillation, and other), end-users (hospitals, cardiac specialty centers, ambulatory surgical centers, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).
By Product Type
Dominant Subsegment: Single-Chamber Leadless Pacemakers.
The single-chamber leadless pacemakers segment accounted for 68% of the Leadless Pacemakers market in 2025. Single-chamber devices, such as Medtronic's Micra VR/VR2 and Abbott's Aveir VR, are the leading product type because they address the largest historically approved patient population, those requiring ventricular-only pacing for bradycardia with normal sinus rhythm, and because they carry the longest clinical track record, the broadest base of trained implanters, and the most established reimbursement pathways. Their smaller regulatory and procedural footprint has allowed single-chamber systems to achieve the widest hospital and specialty-center penetration to date. While dual-chamber leadless pacemakers are the fastest-growing product type, propelled by Abbott's Aveir DR i2i platform unlocking therapy for patients needing atrioventricular synchrony, the depth of clinical experience, established indications, and procedural simplicity of single-chamber systems secure the segment's leadership across the forecast period.
By Technology
Dominant Subsegment: Active Fixation Technology.
The active fixation technology segment accounted for 58% of the Leadless Pacemakers market in 2025. Active fixation, in which a helix or screw-in mechanism secures the device directly to the endocardium, is the leading technology because it provides more reliable long-term lead-free attachment, lower dislodgement risk, and, in systems such as Abbott's Aveir platform, enables device retrievability for replacement or repositioning. Nearly all commercially approved leadless pacemakers, including Medtronic's Micra family and Abbott's Aveir VR, AR, and DR systems, rely on active fixation, reinforcing its dominant position. Wireless device-to-device communication, the enabling technology behind dual-chamber i2i synchronization and future multi-device coordination, is the fastest-growing technology category as dual-chamber and CRT-oriented systems scale, while passive fixation and other emerging approaches, including EBR Systems' ultrasound-based leadless left ventricular endocardial pacing, represent smaller but strategically important niches. Nonetheless, the proven reliability and retrievability advantages of active fixation secure its leadership across the forecast period.
Leadless Pacemakers Market Region Analysis
Dominant Region: North America
North America accounted for 42% of the global Leadless Pacemakers market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the concentration of pioneering FDA approvals, including Medtronic's original 2016 Micra approval and Abbott's Aveir VR, AR, and DR approvals, alongside a dense network of high-volume electrophysiology centers, favorable CMS reimbursement pathways, and rapid physician adoption of dual-chamber and CRT-indicated leadless technology. The United States hosts the largest concentration of leadless implant volume and the broadest base of trained implanting physicians, and Abbott has reported accelerating Aveir adoption driving double-digit growth in its cardiac rhythm management business. Ongoing CMS Coverage with Evidence Development studies and the 2025 approval and Medicare evaluation of EBR Systems' WiSE CRT System further reinforce the region's regulatory and reimbursement leadership, anchoring North America's continued dominance across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Leadless Pacemakers market. The region's elevated CAGR is driven by rising cardiovascular disease prevalence, expanding electrophysiology infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's domestic manufacturers, including MicroPort Scientific Corporation and Lepu Medical, are localizing cardiac rhythm management portfolios and building implant capability; Japan is expanding electrophysiology training, and India is scaling access following Abbott's November 2024 Aveir VR launch and the October 2025 launch of the country's first dual-chamber Aveir implant at Max Hospital, Saket. Government healthcare investment, an expanding base of trained implanting physicians, and rising awareness of minimally invasive pacing options are accelerating adoption, positioning Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 42% of the global Leadless Pacemakers market revenue in 2025. The United States dominates on the strength of its pioneering FDA approval history, dense electrophysiology infrastructure, favorable CMS reimbursement pathways, and the accelerating commercial rollout of Abbott's Aveir DR dual-chamber and EBR Systems' WiSE CRT platforms, while ongoing Coverage with Evidence Development studies reinforce continued adoption.
Europe
Europe is a large and advanced regional market, supported by established CE Mark regulatory pathways, a strong base of academic electrophysiology centers, and growing adoption of next-generation devices such as Medtronic's Micra AV2 and VR2, which received CE Mark approval in January 2024. Manufacturers including BIOTRONIK and OSYPKA maintain a strong regional manufacturing and clinical presence across Germany, France, the United Kingdom, Italy, and Spain, supporting continued adoption of leadless pacing technology.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular disease incidence, expanding electrophysiology infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Localization efforts by MicroPort Scientific Corporation and Lepu Medical in China, alongside Abbott's expanding Aveir footprint in India, are accelerating regional adoption and clinical-training activity.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding cardiac-care infrastructure, rising diagnosis rates for bradyarrhythmia and conduction disorders, and gradual introduction of leadless pacing technology by global manufacturers are broadening access, while training partnerships and distributor relationships support the build-out of regional implant capability.
Leadless Pacemakers Market Competitive Landscape
The Leadless Pacemakers market is classified as Highly Concentrated. Abbott and Medtronic together anchor the top tier through deep patent estates, long-running registry datasets, and captive delivery-tool ecosystems, with Abbott leveraging i2i communication for dual-chamber pacing and Medtronic sustaining broad payer coverage through its accelerometer-based AV-synchrony algorithm. Boston Scientific is advancing its Empower Modular Pacing System, aiming to integrate subcutaneous ICD therapy with leadless pacing, while EBR Systems has established a differentiated position in leadless CRT following its 2025 WiSE System approval. Established cardiac rhythm management manufacturers, including BIOTRONIK, MicroPort Scientific Corporation, Lepu Medical, OSYPKA, Shree Pacetronix, and Oscor, compete through regional manufacturing strength, distribution reach, and adjacent device portfolios, increasing competitive intensity as leadless technology adoption broadens.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Highly concentrated, with Abbott and Medtronic anchoring the market and a growing field of specialized and regional challengers.
- Leading players: Abbott and Medtronic lead through deep patent estates, long-running registry data, and captive delivery-tool ecosystems.
- Geographic reach: Leaders operate global commercial networks with deep penetration in North America and Europe and expanding footprints in Asia-Pacific.
- Product portfolio strength: Top players offer single-chamber, dual-chamber, and, increasingly, CRT-oriented leadless platforms with wireless device-to-device communication.
- Clinical evidence base: Long-term registry and Coverage with Evidence Development data, including Micra CED and Aveir VR, AR, and DR studies, is a decisive competitive advantage.
- Strategic partnerships: Collaborations such as Orchestra BioMed's 2025 financing from Medtronic and Ligand Pharmaceuticals to advance late-stage cardiology programs extend innovation reach.
- Regional manufacturing: Companies including MicroPort Scientific Corporation and Lepu Medical are localizing cardiac rhythm management manufacturing in China to build domestic volume advantage.
- Manufacturing capabilities: Miniaturized capsule engineering, active-fixation delivery systems, and wireless synchronization electronics are key competitive moats.
- Innovation focus: Dual-chamber synchronization, leadless CRT, extended battery life, device retrievability, and multi-device compatibility.
Leadless Pacemakers Market Recent Developmental Activities
In October 2025, Abbott and Max Hospital, Saket, announced the launch of India's first dual-chamber leadless Aveir pacemaker implant, expanding access to next-generation cardiac rhythm management technology.
In 2025, Abbott reported that accelerating adoption of its AVEIR leadless pacemaker portfolio drove double-digit growth in its Cardiac Rhythm Management business, following the 2023 approval of the dual-chamber AVEIR DR system.
Leadless Pacemakers Market Segmentation
Leadless Pacemakers Market by Product Type
- Single-Chamber Leadless Pacemakers
- Dual-Chamber Leadless Pacemakers
Leadless Pacemakers Market by Technology
- Passive Fixation Technology
- Active Fixation Technology
- Wireless Device-to-Device Communication
- Others
Leadless Pacemakers Market by Indication
- Bradycardia
- Atrioventricular (AV) Block
- Atrial Fibrillation
- Other
Leadless Pacemakers Market by End-User
- Hospitals
- Cardiac Specialty Centers
- Ambulatory Surgical Centers
- Others
Leadless Pacemakers Market by Geography
- North America Leadless Pacemakers Market
- United States Leadless Pacemakers Market Size in USD million (2023-2034)
- Canada Leadless Pacemakers Market Size in USD million (2023-2034)
- Mexico Leadless Pacemakers Market Size in USD million (2023-2034)
- Europe Leadless Pacemakers Market
- Germany Leadless Pacemakers Market Size in USD million (2023-2034)
- United Kingdom Leadless Pacemakers Market Size in USD million (2023-2034)
- France Leadless Pacemakers Market Size in USD million (2023-2034)
- Italy Leadless Pacemakers Market Size in USD million (2023-2034)
- Spain Leadless Pacemakers Market Size in USD million (2023-2034)
- Rest of Europe Leadless Pacemakers Market Size in USD million (2023-2034)
- Asia-Pacific Leadless Pacemakers Market
- China Leadless Pacemakers Market Size in USD million (2023-2034)
- Japan Leadless Pacemakers Market Size in USD million (2023-2034)
- India Leadless Pacemakers Market Size in USD million (2023-2034)
- Australia Leadless Pacemakers Market Size in USD million (2023-2034)
- South Korea Leadless Pacemakers Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Leadless Pacemakers Market Size in USD million (2023-2034)
- Rest of the World (RoW) Leadless Pacemakers Market
- Middle East Leadless Pacemakers Market Size in USD million (2023-2034)
- Africa Leadless Pacemakers Market Size in USD million (2023-2034)
- South America Leadless Pacemakers Market Size in USD million (2023-2034)
Key Takeaways from the Leadless Pacemakers Market Report Study
- Market size analysis for the current leadless pacemakers market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global leadless pacemakers market.
- Various opportunities available for competitors in the leadless pacemakers market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current leadless pacemakers market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for leadless pacemakers market growth in the future?
Target audience who can benefit from this leadless pacemakers market report study
- Leadless pacemakers product providers
- Research organizations and consulting companies
- Neurodegenerative disease therapeutics-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in leadless pacemakers
- Various end-users who want to know more about the leadless pacemakers market and the latest technological developments in the leadless pacemakers market.
Frequently Asked Questions:
Q1. What is the growth rate of the leadless pacemakers market?
The leadless pacemakers market is projected to expand at a CAGR of 9.6% during the forecast period from 2026-2034.
Q2. What is the market size of the leadless pacemakers market?
The leadless pacemakers market is estimated at USD 427.7 million in 2025 and is projected to reach USD 1,000.1 million by 2034.
Q3. Which region dominates the leadless pacemakers market?
North America dominated the Leadless Pacemakers market with a 42% share of global revenue in 2025, supported by pioneering FDA approvals, dense electrophysiology infrastructure, favorable CMS reimbursement pathways, and the largest concentration of trained implanting physicians. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the leadless pacemakers market?
The principal drivers are the commercial expansion of dual-chamber leadless pacing following Abbott's 2023 AVEIR DR approval; the rising global cardiovascular disease and bradyarrhythmia burden, with the World Health Organization attributing nearly 17.9 million deaths annually to cardiovascular disease; the clinical shift toward minimally invasive, lead-free rhythm management; next-generation product approvals such as Medtronic's Micra AV2 and VR2; and the 2025 entry of leadless technology into cardiac resynchronization therapy through EBR Systems' WiSE CRT System.
Q5. Who are the major players in the leadless pacemakers market?
The major players include Abbott, Medtronic, BIOTRONIK, Boston Scientific, MicroPort Scientific Corporation, Lepu Medical, OSYPKA, Shree Pacetronix, EBR Systems, and Oscor, among other active manufacturers profiled in the Competitive Landscape section. Abbott and Medtronic lead the market through dual-chamber and next-generation single-chamber platform depth.
Table of Contents
1. Leadless Pacemakers Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
2. Leadless Pacemakers Market Executive Summary
- 2.1 Market at a Glance
3. Leadless Pacemakers Market Key Factors Analysis
- 3.1 Leadless Pacemakers Market Drivers
- 3.1.1 Commercial Expansion of Dual-Chamber Leadless Pacing
- 3.1.2 Rising Global Cardiovascular Disease Burden
- 3.1.3 Shift Toward Minimally Invasive, Lead-Free Rhythm Management
- 3.1.4 Entry into Cardiac Resynchronization Therapy
- 3.2 Leadless Pacemakers Market Restraints and Challenges
- 3.2.1 High Device Cost and Reimbursement Variability
- 3.2.2 Procedural Complexity and Training Requirements
- 3.2.3 Safety Surveillance and Device Retrieval Considerations
- 3.3 Leadless Pacemakers Market Opportunities
- 3.3.1 Leadless Cardiac Resynchronization Therapy Expansion
- 3.3.2 Emerging-Market Access and Physician Training
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
6. Leadless Pacemakers Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
7. Leadless Pacemakers Market Assessment
- 7.1 By Product Type
- 7.1.1 Single-Chamber Leadless Pacemakers
- 7.1.2 Dual-Chamber Leadless Pacemakers
- 7.2 By Technology
- 7.2.1 Passive Fixation Technology
- 7.2.2 Active Fixation Technology
- 7.2.3 Wireless Device-to-Device Communication
- 7.2.4 Others
- 7.3 By Indication
- 7.3.1 Bradycardia
- 7.3.2 Atrioventricular (AV) Block
- 7.3.3 Atrial Fibrillation
- 7.3.4 Other
- 7.4 By End-Users
- 7.4.1 Hospitals
- 7.4.2 Cardiac Specialty Clinics
- 7.4.3 Ambulatory Surgical Centers
- 7.4.4 Others
- 7.5 By Geography
- 7.5.1 North America
- 7.5.1.1 United States Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.1.2 Canada Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.1.3 Mexico Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.2 Europe
- 7.5.2.1 Germany Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.2.2 United Kingdom Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.2.3 France Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.2.4 Italy Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.2.5 Spain Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.2.6 Rest of Europe Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.3 Asia-Pacific
- 7.5.3.1 China Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.3.2 Japan Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.3.3 India Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.3.4 Australia Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.3.5 South Korea Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.3.6 Rest of Asia-Pacific Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.4 Rest of World
- 7.5.4.1 Middle East Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.4.2 Africa Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.4.3 South America Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.1 North America
8. Leadless Pacemakers Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
9. Leadless Pacemakers Market Startup Funding and Investment Trends
10. Leadless Pacemakers Market Company and Product Profiles
- 10.1 Abbott
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 Medtronic
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 BIOTRONIK
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 Boston Scientific Corporation
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 MicroPort Scientific Corporation
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 Lepu Medical
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 OSYPKA
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 Shree Pacetronix
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 EBR Systems
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
10. Oscor
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
